文献速递类风湿关节炎

按基线体重指数分层评估托法替布在类风湿关节炎患者中的疗效:三项3期研究汇总数据的分析

Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by baseline body mass index: an analysis of pooled data from phase 3 studies.
PubMed 文献 · RMD Open · 2022-01-01

该事后分析汇总6项3期研究数据,按基线体重指数(<25、25至<30、≥30 kg/m2)分层,描述性评估托法替布5 mg或10 mg每日两次与安慰剂相比在类风湿关节炎患者中的疗效。结果显示各体重指数类别中托法替布疗效均优于安慰剂,且各治疗组内不同体重指数类别间疗效差异通常无临床意义;回归分析中体重指数与所选结局无一致关联。

要点

  • 共纳入3880例患者,基线体重指数<25、25至<30、≥30 kg/m2者分别占43.6%、30.2%、26.2%。
  • 各体重指数类别中托法替布疗效改善均优于安慰剂。
  • 各治疗组内不同体重指数类别间疗效差异通常无临床意义,体重指数与所选结局无一致关联。

核心结论

  • 基线体重指数未一致影响托法替布应答,提示托法替布是无论基线体重指数如何(包括体重指数≥30 kg/m2)的中重度类风湿关节炎成人患者的有效口服治疗选择。

研究设计与样本

  • 事后分析汇总6项3期研究数据,患者接受托法替布5 mg(N=1589)或10 mg(N=1611)每日两次或安慰剂(第3或6个月转为活性治疗;N=680),联合或不联合传统合成改善病情抗风湿药,按基线体重指数(<25、25至<30、≥30 kg/m2)分层,终点评估至第6个月,采用描述性分析,部分结局用多变量模型校正,并用单变量/多变量回归分析确定第6个月结局的预测因素。

主要发现

  • 共纳入3880例患者,基线体重指数<25、25至<30、≥30 kg/m2者分别为1690例(43.6%)、1173例(30.2%)、1017例(26.2%)。
  • 各体重指数类别中托法替布与安慰剂相比均显示更大的疗效改善。
  • 各治疗组内不同体重指数类别间疗效结局(校正与未校正)差异通常无临床意义。
  • 回归分析中体重指数与所选结局无一致关联。

临床怎么用

  • 原文结论未据此给出推荐,仅指出托法替布是无论基线体重指数如何(包括体重指数≥30 kg/m2)的中重度类风湿关节炎成人患者的有效口服治疗选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Tofacitinib is an oral Janus kinase for the treatment of rheumatoid arthritis (RA). This post hoc analysis assessed whether baseline body mass index (BMI) impacts tofacitinib efficacy in patients with RA. METHODS: Pooled data from six phase 3 studies in patients receiving tofacitinib 5 mg (N=1589) or 10 mg (N=1611) twice daily or placebo (advancing to active treatment at months 3 or 6; N=680), ±conventional synthetic disease-modifying antirheumatic drugs, were stratified by baseline BMI (<25, 25 to <30, ≥30 kg/m2). Endpoints (through to month 6) were assessed descriptively: American College of Rheumatology 20/50/70 response rates; changes from baseline (∆) in Disease Activity Score in 28 joints, erythrocyte sedimentation rate (DAS28-4(ESR)), DAS28-4(C-reactive protein), Clinical Disease Activity Index (CDAI), Health Assessment Questionnaire-Disability Index (HAQ-DI) and pain; and proportions of patients achieving DAS28-4(ESR) ≥1.2 and HAQ-DI ≥0.22 decreases from baseline, low disease activity (DAS28-4(ESR) ≤3.2 or CDAI ≤10) and radiographic non-progression (Δmodified Total Sharp Score ≤0.5; months 12 and 24). Estimates were adjusted using multivariable models for selected outcomes. Univariate/multivariable regression analyses determined predictors of month 6 outcomes. RESULTS: Of 3880 patients included, 1690 (43.6%), 1173 (30.2%) and 1017 (26.2%) had baseline BMI <25, 25 to <30 and ≥30 kg/m2, respectively. Tofacitinib showed greater efficacy improvements versus placebo in each BMI category. Differences in efficacy outcomes (adjusted and unadjusted) were generally not clinically meaningful across BMI categories within treatment groups. In regression analyses, BMI was not consistently associated with selected outcomes. CONCLUSIONS: Baseline BMI did not consistently affect tofacitinib response suggesting that tofacitinib is an effective oral treatment option for adults with moderate to severe RA regardless of baseline BMI, including patients with BMI ≥30 kg/m2. TRIAL REGISTRATION NUMBERS: NCT00814307, NCT01039688; NCT00960440; NCT00847613; NCT00856544; NCT00853385.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Dikranian AH, Gonzalez-Gay MA, Wellborne F, et al. Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by baseline body mass index: an analysis of pooled data from phase 3 studies. RMD Open. 2022. PMID: 35577477. doi:10.1136/rmdopen-2021-002103

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。